



One year since the first COVID-19 vaccine approval in the EU



Overview of EMA recommendations



COVID-19 vaccines and treatments




5 Vaccines authorised for use in the EU

- Comirnaty (BioNTech and Pfizer)
- Spikevax (Moderna)
- Vaxzevria (AstraZeneca)
- COVID-19 Vaccine Janssen
- Nuvaxovid (Novavax)



6 Treatments authorised for use in the EU

- Veklury (remdesivir)
- Regkirona (regdanvimab)
- Ronapreve (casirivimab / imdevimab)
- RoActemra (tocilizumab)
- Xevudy (sotrovimab)
- Kineret (anakinra)



4 Vaccines under evaluation

- Sputnik V, Gam-COVID-Vac (Gamaleya Institute)
- COVID-19 Vaccine (Vero Cell) Inactivated (Sinovac)
- Vidprevtyn (Sanofi Pasteur)
- VLA2001 (Valneva)



4 Treatments under evaluation

- Evusheld (tixagevimab / cilgavimab)
- Paxlovid (PF-07321332 / ritonavir)
- Lagevrio (molnupiravir)
- Olumiant (baricitinib)

As of 21 December 2021

COVID-19 vaccination in the European Union



78.4 % of the EU adult population fully vaccinated



1.074 billion doses delivered



Source: [European Commission](https://ec.europa.eu/commission/presscorner/detail/en/ip21_1917) (as of 17 December 2021)